Related Experiment Video
Updated: Nov 21, 2025

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
Published on: May 5, 2014
Favipiravir in Therapy of Viral Infections
Ryta Łagocka1, Violetta Dziedziejko2, Patrycja Kłos2
1Department of Conservative Dentistry and Endodontics, Pomeranian Medical University, 70-204 Szczecin, Poland.
Abstract:
Favipiravir (FPV) is a novel antiviral drug acting as a competitive inhibitor of RNA-dependent RNA polymerase (RdRp), preventing viral transcription and replication. FPV was approved in Japan in 2014 for therapy of influenza unresponsive to standard antiviral therapies. FPV was also used in the therapy of Ebola virus disease (EVD) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In this review, we discuss the mechanisms of action, pharmacokinetic parameters, toxicity, and adverse effects of FPV, as well as clinical studies evaluating the use of FPV in the therapy of influenza virus (IV) infection, EVD, and SARS-CoV-2 infection, along with its effectiveness in treating other human RNA infections.
More Related Videos
Related Concept Videos
Subviral Agents
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Retrovirus Life Cycles
Myocarditis III: Medical Management
Retroviruses
Drug Therapy
Antianxiety Medications

